key: cord-0490767-4hu81mhh
authors: Jimenez-Munguia, Irene; Beaven, Andrew H.; Blank, Paul S.; Sodt, Alexander J.; Zimmerberg, Joshua
title: Interferon-induced transmembrane protein 3 (IFITM3) and its antiviral activity
date: 2022-04-06
journal: nan
DOI: nan
sha: 2481383dfd646a2b68ab0a28d508f986d23cb2a3
doc_id: 490767
cord_uid: 4hu81mhh

Enveloped viral infections require fusion with cellular membranes for viral genome entry, occurring only following interaction of viral and cellular membranes allowing fusion pore formation, by which the virus accesses the cytoplasm. Here, we focus on interferon-induced transmembrane protein 3 (IFITM3) and its antiviral activity. IFITM3 is predicted to block or stall viral fusion at an intermediate state, causing viral propagation to fail. After introducing IFITM3, we describe the generalized lipid membrane fusion pathway and how it can be stalled, particularly with respect to IFITM3, and current questions regarding IFITM3's topology. Specific emphasis is placed on IFITM3's amphipathic a-helix (AAH) 59V-68M, necessary for antiviral activity. Calculations are reported of hydrophobicity and hydrophobic moment of this peptide and active site peptides from other membrane-remodeling proteins. Finally, we discuss the effects of post-translational modifications and localization, how IFITM3's AAH may block viral fusion, and possible ramifications of membrane composition.

million deaths annually are associated with acute lower respiratory tract infections and in pandemic years the flu is a top human killer [2] . Influenza virus, even in non-pandemic years, is responsible for killing 250,000-500,000 people globally with an associated annual cost ranging from billion USD [2] . The spectre of more frequent and prolonged viral pandemics, like COVID-19, highlight the urgency for advanced research and development of pan-viral therapeutics.

Human immune response against viral infections involves the activation of interferon (IFN) signaling [3] . Viral binding to pattern recognition receptors (PRRs) trigger the synthesis and secretion of IFNs, which induces IFN-stimulated genes (ISGs) [3] leading to synthesis of ~2000 proteins. Specifically, IFN type I (α) and II (g) stimulate the production of the interferon-induced transmembrane protein family (IFITMs) [3] . The human IFITM protein family consists of five members (IFITM1, 2, 3, 5, and 10) located on chromosome 11 [4] . IFITM3 is potent against several enveloped viruses including Dengue, Influenza A (IAV) H1N1, Zika, coronavirus, hepatitis C, West Nile Virus, vesicular stomatitis virus (VSV) and human immunodeficiency virus (HIV), SARS-CoV2 [5, 6] .

Enveloped viral infection is mediated by fusion of the viral envelope to either the plasma membrane or endosomal membrane (after update by endocytosis). For viral-endosomal membrane fusion, it is triggered by some combination of low pH, receptor binding in acidic conditions, and the action of protease [7] . How IFITM stabilizes cellular membranes against viral envelope fusion is not well defined; even the stage in which IFITM interferes is contradictory [8, 9] . Here, the recently proposed mechanisms for IFITM3's antiviral activity will be evaluated, specifically how IFITM3 interacts with membrane lipids to impair viral-host membrane fusion and thus viral cell entry [10, 11] . After introducing IFITM3, as well as the generalized lipid membrane fusion pathway, this review will summarize early work on the topology and secondary structure of IFITM3, delineating attempts to isolate the membrane-interacting parts of IFITM3. This will culminate in a detailed discussion of IFITM3's amphipathic a-helix region 59V-68M; hereafter referred to as IFITM3's AAH. The next section reviews recent work linking IFITM3's AAH activity to the topology, localization, and aggregation of IFITM3. The impact of post-translational modifications on IFITM3's activity (specifically S-palmitoylation that induces membrane remodeling) follows. Finally, the role of membrane cholesterol will be discussed.

The interferon-induced transmembrane protein 3. IFITM3 has been implicated in a number of cellular functions including cell adhesion, stem cell migration, and leucocyte apoptosis [12] .

Ubiquitously expressed in endothelial cells [13] , its intracellular localization is mainly at endosomal and lysosomal membranes, although it is identified also in plasma and endoplasmic reticulum membranes in unstimulated cells with further distribution in membrane-derived vesicles after IFN stimulation [14, 15] . IFITM3 is active against viruses that enter cells via pH-dependent or pH-independent fusion (e.g., influenza A or HIV, respectively) in the endosomal pathway [16] .

That is, the antiviral activity of IFITM3 against enveloped viruses is exerted at the early stages of virus replication -after virus binds to the cell's surface but prior to viral mRNA production [14] .

In the endosomal pathway, IFITM3 does not affect viral binding to surface receptors, virus endocytosis, or trafficking of viruses to late endosomes [14] . Instead, the loss of viral RNA in acidic inclusions of IFITM3-producing cells infected with H1N1 suggests virus entrapment in acidic compartments with further lysosomal degradation [14] . This implies that IFITM3 interferes with the virus-endosomal membrane fusion process irrespective of receptor binding and endosomal trafficking [9, 17, 18] . At hemifusion, there is no substantial cellular uptake of viral material. Only viral lipid content has mixed. If stalled at hemifusion, the endosome will traffick to the lysosome and degrade the virus -preventing replication. Thus, cellular antiviral proteins can stall the pathway at hemifusion by shifting leaflet curvature preference [29, 30] . For example, lipids with positive monolayer intrinsic curvature (e.g., lyso-phosphatidylcholine) inhibit hemifusion when added to the proximal leaflets (e.g., virus outer and endosome inner) and facilitate pore formation when added to distal leaflets (e.g., virus inner and endosome outer). Conversely, lipids with negative monolayer intrinsic curvature (e.g., phosphatidylethanolamine) facilitate hemifusion when added to proximal leaflets and inhibit pore formation when added to distal leaflets.

The viral entry route occurs as follow: 1) Virus is bound to the cell surface by a specific-receptor recognition. 2) Virus experiences receptor-mediated endocytosis. 3a) Virus is trafficked from the early endosomes to the late endosomes, during which time acidification of endosome triggers the activation of the virus fusion protein to induce fusion between the virus and endosome membranes. Fusion pore formation allows viral genome release into the cell's cytoplasm for further initiation of viral replication in the nuclei. Viral entry is blocked by IFITM3 by prevention of virus release from late endosomes (red T). 3b) Virus is trapped in late endosomes at the hemifusion stage (4) in which the fusion pore formation is prevented by the amphipathic helix (AH) of IFITM3 (black rectangle). The leaflet associated with markers (a), (e), and (f) is the endosome outer leaflet only. The leaflet associated with marker (b) is the viral envelope's inner leaflet only. The hemifused leaflet joining endosome inner leaflet with viral envelope outer leaflet is marked by (c). Also, note that (a) IFITM3 can aggregate or work alone to block the fusion pathway, and 4b) IFITM3 could work by its incorporation into the viral envelope.

The IFITM3 dilemma in the fusion pathway. Is it possible that IFITM3 acts like an aforementioned lipid that inhibits fusion? While IFITM3's membrane fusion disruption is implicated experimentally [10, [31] [32] [33] [34] [35] [36] [37] , but the (1) stage and (2) mechanism by which IFITM3 interferes in the fusion process is unclear.

(1) Whereas cell-cell fusion is inhibited before hemifusion [8] (viral fusion proteins expressed on the plasma membrane), viral fusion with endosomes is blocked after hemifusion [9] . This is a radical difference -the cell-cell fusion assay that evaluates plasma membrane-plasma membrane fusion shows IFITM-dependent blockage of fusion at hemifusion [8] , but when fusion is evaluated in the context of viral infections (e.g. endosomes containing viral particles), hemifusion between the viral and endosomal membranes occurs [9] with subsequent blockage either of fusion pore formation or expansion.

(2) In both experiments, the authors invoke IFITM3-dependent alteration of membrane curvature to explain the stage at which fusion is blocked, but each group invokes the opposite cuvature [8] [9] [10] ! For endosomal fusion, the antifusion activity of IFITM3 to its AAH [38] . Clearly, it is imperative that experiments and modeling be performed to determine if the IFITM3's AAH produces positive [8] or negative [11] leaflet intrinsic curvature.

To evaluate IFITM3's mechanism on a specific leaflet, we must know how the protein and its membrane domains are oriented in the bilayer. However, IFITM3's 133 residues can be distributed across the membrane in a variety of topologies ( Figure 2 ).

A) Two pass transmembrane protein with its N-and C-terminus exposed in the endosome lumen (extracellularly) [15] . B) An intramembrane protein with its N-and C-terminus exposed in the cytoplasm [16, 32] . C) Type II transmembrane protein with its N-terminus exposed in the cytoplasm and its C-terminus exposed in the lumen [39] . D) A single long transmembrane helix with its N-terminus exposed in the cytoplasm, its C-terminus exposed in the lumen, and an intramembrane segment in the cytoplasmic leaflet (corresponding to two regions detected by NMR that interact with the membrane) [40] . E) As in (D) but with the middle a-helix in the cytoplasm. For linear sequence and secondary structure determinations, see Figure 1A of Chesarino et al. [38] .

Indeed, IFITM3's topology in the membrane may be uncertain because sub-populations of IFITM3 could shift orientation upon specific stimuli: biochemical evidence appears to contradict a single topology [39, 41, 42] . Additionally, topologies C-E require long transmembrane domains. [10] For example, the structure predicted in Chesarino et al. suggests a transmembrane domain that is ~58.6 Å long (each residue contributes 1.5 Å rise); nearly twice the length of a prototypical membrane thickness of ~30 Å. Indeed, all-atom MD simulations of IFITM3 displayed severe TM tilt angles [43] . The unusual length of the domain may indicate that this feature is less topologically stable than common TM lengths. Nevertheless, it is likely that IFITM3 has a Cterminus facing the lumen, a transmembrane section, and an intramembrane portion at the Nterminus (this is true in the four most recently proposed topologies). Already these features constrain hypotheses of how IFITM3 prevents viral infections by blocking fusion. For example, topologies B-E have a-helices predicted to be embedded in the cytoplasmic leaflet. The leaflet in which the AAHs lies is an important characteristic for determining how IFITM3 blocks fusion pores.

The amphipathic region 59V-68M of IFITM3. The hydrophobic moment of IFITM3's (59V-68M; see topology E, Figure 2 ) appears to be correlated with the antiviral activity of IFITM3, since mutating or deleting this region decreases IFITM3's antiviral efficacy [10, 11] . To compare mutated and wild-type AAH to other amphipathic helices, we replicated the hydrophobic moment calculation of region 59V-68M using HELIQUEST [44] (Figure 3 and Table 1 ). We highlight the 65F insertion mutation that has nearly the same hydrophobicity as wild type, but a distinctly different hydrophobic moment. The hydrophobic moment likely determines how anchored the peptide remains at the leaflet-water interface [45] . Strong anchoring above or below the leaflet's neutral surface would generate positive curvature or negative curvature, respectively. Therefore, we anticipate the hydrophobic moment to correlate with curvature generated by the peptide [46] . [44] bioinformatic tool was used to plot the protein region 59V-68M of IFITM3 with antiviral activity and the same protein region with a phenylalanine inserted in position 65 (59V-65F-69M) with diminished antiviral activity. 〈 〉 and 〈 〉 indicate hydrophobicity and hydrophobic moment values, respectively. The helical wheel for 59V-68M with antiviral activity, and the inserted 65F version with diminished antiviral activity are shown. Hydrophilic and hydrophobic amino acids are colored in purple and yellow, respectively. Red letters indicate the N-and C-terminus. The arrow length and direction represents the hydrophobic moment. The theoretical range for hydrophobicity and hydrophobic moment are: 〈 〉 from 1.01 to 2.25 and 〈 〉 from 0 to 3.26. [44] . HELIQUEST was also used by Chesarino et al. (see Table EV1 in that work) [10] . The hydrophobic moments (theoretical range of 0 to 3.26) for IFITM3's 59V-68M and mutants are compared to arginine-rich cell-penetrating peptides (A2-17) [46] , the ALPS1 domain of human ARFGAP1 [47] [48] [49] , the predicted AAH region of the bacterial division factor of Bacillus subtilis' divIVA [50, 51] , and piscidins 1 and 3 [52] . The IFITM3 data matches with that published in Chesarino et al. [38] and the trends for A2-17 match Takechi-Haraya et al. [46] (note that A2-17 L14R/R15L increases the duration and charge flux from stable membrane pores compared to A2-17 R10L/L11R). The remaining data are new determinations. It is difficult to make comparisons across studies given methodology differences, but within studies, we can conclude that: i) A2-17 L14R/R15L has a larger hydrophobic moment and induces stronger positive curvature than A2-17 R10L/L11R [46] ; ii) divIVA has a larger hydrophobic moment but induces similar positive curvature to AFRGAP1 [53] ; and iii) piscidin 1 and 3 induce similar positive curvature (in POPC:cholesterol, 4:1 mol%) and have very similar hydrophobic moments [52] . As implied by Chesarino et al. [38] , it appears that hydrophobic moment is a reasonable, but imperfect, indicator of curvature induction.

is reduced by some PTMs, including lysine methylation (88K), tyrosine phosphorylation (20Y) and ubiquitination ( Figure 4) [32, 34, 35] . Conversely, mono-methylation on 88K is induced during infections caused by Vesicular stomatitis virus (VSV) and IAV [54] but demethylation of 88K by histone demethylase LSD1 prevents RNA virus replication, and impairs viral infection [55] .

Furthermore, phosphorylating 20Y blocks the endocytosis signal motif YXXF (of which 20Y is part) leading to a redistribution and accumulation of IFITM3 in the plasma membrane [34, 41] .

Contrapositively, S-palmitoylation helps to anchor IFITM3 to the membrane and promotes its antiviral activity [31]. S-palmitoylation frequently occurs on cysteines adjacent to transmembrane domains, inducing transmembrane domain tilting, and producing weak negative curvature in the embedded leaflet [56, 57] . Indeed, the first all-atom MD simulations of IFITM3 displayed severe TM tilt angles with AAHs bound more strongly to the membrane when Spalmitoylation is present [43] . Defects in IFITM3's S-palmitoylation lead to a different phenotype with less affinity for the membrane and inefficient antiviral activity [32] . In IFITM3, 71-72C and 105C are susceptible to palmitoylation. Considering the close proximity of 71-72C to AAH 59V-68M, palmitoylation on 71-72C could facilitate 59V-68M insertion into the cytoplasmic leaflet of endosomal membranes by increasing the hydrophobicity in the proximal membrane region, stabilizing IFITM3 insertion into endosomal membranes; and consequently, cause inhibition of fusion pore formation.

A) Amino acids described in the literature that are important for the activity of IFITM3. The Nterminus (residues 1-21), which is critical for IFITM3's endosomal localization, is highlighted in purple [16] . In green are two phenylalanine residues (75F and 78F) necessary for the antiviral activity of IFITM3 [58] and two glycine residues (91G and 95G) that represent a GxxxG motif necessary for the IFITM3 dimerization and pore formation impediment [59] . Residues highlighted in orange are post-translational modified amino acids that negatively impact IFITM3 performance including phosphorylated 20Y [16] , ubiquitinated 24K, 83K, and 104K [32], and the ubiquitinated and methylated 88K [32, 54] . In blue are S-palmitoylated cysteines (71-72C and 105C) that positively impact IFITM3 anti-viral performance [60] . The transmembrane domain is colored gray and the AAH (59V-68M) is colored red.

The role of membrane composition. Given that IFITM3 production occurs concurrently with aberrant late endosomal cholesterol accumulation, sterol concentration itself may play a role in the early antiviral defense [61, 62] . For example, the interaction between IFITM3's AAH and the endosomal membrane might be influenced by an increase in the lipid order caused by the accumulation of cholesterol in late endosomes in IFITM3-expresing cells [61, 62] . Additionally, negative Gaussian curvature, which can occur at the necks of fusion pores, has negative mean curvature in both leaflets, leading to a net thinned membrane interior. This thinning might influence sterol distributions around the pore -affecting pore formation energetics.

Supporting this hypothesis, recent work has shown direct evidence that sterols do affect energetic barriers associated with the pore narrowing/widening step in endo-/exocytosis [63, 64] , and a substantial body of work has focused on altering the host's cholesterol metabolism to inhibit enveloped viral replication [65] [66] [67] [68] [69] [70] . Consequently, a hypothesis suggests that each virus has a preferred plasma membrane or endosomal cholesterol content that can affect when and where it targets optimal replication. Recent experiments and simulations have demonstrated that IFITM3's S-palmitoylation interacts directly with endosomal cholesterol, and the quantity of these interactions (i.e., more/less cholesterol or more/less palmitoylation) modulates antiviral activity against IAV, SARS-CoV-2 and EBOV [42] . That said, cholesterol's importance relative to IFITM3 blockage of the hemifusion step is disputed, with experiments suggesting that only the IFITM3 protein is responsible for full fusion blockage [8, 9, 61, 71] . Determining how peptides [72] , cholesterol, and other lipids partition into a pore's saddle curvature, thinned/thickened leaflets, and net thinned membranes is of extreme interest for future experiments, simulations, and theory.

membrane fusion is required for cell entry. IFITM3 significantly affects the progression of viral infections by preventing fusion and blocking viral entry into the cytoplasm [9, 14] . Fusion is impaired by IFITM3's AAH, which allows viral-endosome hemifusion but not full pore formation. 

Forum of International Respiratory Societies

Transcriptional and posttranscriptional regulation of interferon-induced gene expression in human cells

Evolution of vertebrate interferon inducible transmembrane proteins

IFITM3 Restricts Human Metapneumovirus Infection

Opposing activities of IFITM proteins in SARS-CoV-2 infection

Fusion of Enveloped Viruses in Endosomes. Traffic

IFITM Proteins Restrict Viral Membrane Hemifusion

IFITM3 Restricts Influenza A Virus Entry by Blocking the Formation of Fusion Pores following Virus-Endosome Hemifusion

IFITM 3 requires an amphipathic helix for antiviral activity

Interferon-Induced Transmembrane Protein 3 Blocks Fusion of Diverse Enveloped Viruses by Altering Mechanical Properties of Cell Membranes

The small interferon-induced transmembrane genes and proteins

Constitutively Expressed IFITM3 Protein in Human Endothelial Cells Poses an Early Infection Block to Human Influenza Viruses

IFITM3 inhibits influenza a virus infection by preventing cytosolic entry

IFITM Proteins Mediate the Innate Immune Response to Influenza A H1N1 Virus , West Nile Virus and Dengue Virus

The N-Terminal Region of IFITM3 Modulates Its Antiviral Activity by Regulating IFITM3 Cellular Localization

IFITM Proteins Restrict HIV-1 Infection by Antagonizing the Envelope Glycoprotein

Interferon-induced transmembrane protein 3 blocks fusion of sensitive but not resistant viruses by partitioning into virus-carrying endosomes

The Interferon-Stimulated Gene Ifi27l2a Restricts West Nile Virus Infection and Pathogenesis in a Cell-Type-and Region-Specific Manner

IFITM proteins inhibit HIV-1 protein synthesis. Sci Rep

The IFITMs Inhibit Zika Virus Replication

Phosphorylation of the Antiviral Protein Interferon-inducible Transmembrane Protein 3 (IFITM3) Dually Regulates Its Endocytosis and Ubiquitination

Regulation of the trafficking and antiviral activity of IFITM3 by post-translational modifications

More than meets the I: The diverse antiviral and cellular functions of interferon-induced transmembrane proteins

IFITM3 reduces retroviral envelope abundance and function and is counteracted by glycogag

IFITM 3 requires an amphipathic helix for antiviral activity

Interferon-induced transmembrane protein 3 is a type II transmembrane protein

Combined approaches of EPR and NMR illustrate only one transmembrane helix in the human IFITM3

Identification of an endocytic signal essential for the antiviral action of IFITM3

Spalmitoylation and sterol interactions mediate antiviral specificity of IFITM isoforms

Site-Specific Lipidation Enhances IFITM3 Membrane Interactions and Antiviral Activity

HELIQUEST: A web server to screen sequences with specific α-helical properties

Effect of hydrophobic moment on membrane interaction and cell penetration of apolipoprotein E-derived arginine-rich amphipathic α-helical peptides

Effect of hydrophobic moment on membrane interaction and cell penetration of apolipoprotein E-derived arginine-rich amphipathic α-helical peptides

Lipid packing sensed by ArfGAP1 couples COPI coat disassembly to membrane bilayer curvature

ArfGAP1 responds to membrane curvature through the folding of a lipid packing sensor motif

Amphipathic lipid packing sensor motifs: probing bilayer defects with hydrophobic residues

Computer programs to identify and classify amphipathic alpha helical domains

Localisation of DivIVA by targeting to negatively curved membranes

The Curvature Induction of Surface-Bound Antimicrobial Peptides Piscidin 1 and Piscidin 3 Varies with Lipid Chain Length

Molecular modeling of lipid membrane curvature induction by a peptide: More than simply shape

Negative regulation of interferon-induced transmembrane protein 3 by SET7-mediated lysine monomethylation

Histone demethylase LSD1 restricts influenza A virus infection by erasing IFITM3-K88 monomethylation

What does S-palmitoylation do to membrane proteins?

Palmitoylation Contributes to Membrane Curvature in Influenza A Virus Assembly and Hemagglutinin-Mediated Membrane Fusion

The CD225 Domain of IFITM3 Is Required for both IFITM Protein Association and Inhibition of Influenza A Virus and Dengue Virus Replication

Homologyguided identification of a conserved motif linking the antiviral functions of IFITM3 to its oligomeric state

Palmitoylome profiling reveals S-palmitoylation-dependent antiviral activity of IFITM3

The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry

Late endosomal/lysosomal cholesterol accumulation is a host cellprotective mechanism inhibiting endosomal escape of influenza A virus

Sterols Lower Energetic Barriers of Membrane Bending and Fission Necessary for Efficient Clathrin Mediated Endocytosis

Vesicle cholesterol controls exocytotic fusion pore

Antiviral effects of statins

The cholesterol metabolite 27-hydroxycholesterol inhibits SARS-CoV-2 and is markedly decreased in COVID-19 patients

25-Hydroxycholesterol is a potent SARS-CoV-2 inhibitor

Targeting Cholesterol Metabolism as Efficient Antiviral Strategy Against the Hepatitis E Virus

Endosomal Cholesterol in Viral Infections -A Common Denominator?

Oxysterols in the Immune Response to Bacterial and Viral Infections

Amphotericin B Increases Influenza A Virus Infection by Preventing IFITM3-Mediated Restriction

Bicontinuous inverted cubic phase stabilization as an index of antimicrobial and membrane fusion peptide activity

Acknowledgements. This work was supported by the intramural program of the NICHD. AHB was supported by a Postdoctoral Research Associate (PRAT) fellowship from the National Institute of General Medical Sciences (NIGMS), award number 1Fi2GM137844-01. Figure 1 was drawn on biorender.com, and Figure 4 was created with the Protter webtool and Inkscape.